#USA #Class Action #San Francisco #Hagens Berman #Grail Inc.

GRAIL, Inc. Investors Take Note: Class Action Opportunity

A recent investigation by national shareholder rights firm Hagens Berman has sparked an important call to action for investors of GRAIL, Inc. (NASDAQ: GRAL) who have suffered substantial financial losses. Allegations have emerged surrounding the company’s purported violations of U.S. securities laws, particularly relating to its flagship NHS-Galleri cancer screening trial. This situation presents an opportunity for affected shareholders to step forward and join a class action lawsuit.

The Allegations

The pending litigation focuses on claims suggesting that GRAIL misled its investors about the clinical design and effectiveness of the NHS-Galleri trial. The trial was crucial in establishing the efficacy of GRAIL's cancer screening capabilities. Hagens Berman’s investigation brings to light serious findings regarding how the company communicated the trial’s potential capabilities to its stakeholders, specifically around many critical aspects:

• - Insufficient Trial Design: The firm alleges that GRAIL failed to disclose essential internal data trends indicating that the three-year follow-up timeframe for the trial was insufficient to meet its primary endpoint, which was aimed at demonstrating significant reductions in the diagnoses of late-stage cancers.
• - Withheld Data: The investigation contends that GRAIL selectively oversold positive topline results while withholding pertinent granular information which would have illustrated a lower likelihood of success.
• - Misrepresentation of Progress: GRAIL's assurances to investors regarding the robustness of the study and its international expansion plans were allegedly not supported by the underlying facts, as various indicators suggested otherwise.

These bold claims culminated in a disclosure on February 19, 2026, when GRAIL revealed the unfortunate news that the NHS-Galleri trial failed to meet its primary goal of reducing late-stage cancer diagnoses significantly. The findings prompted a dramatic 50.55% drop in stock prices within a single day, resulting in a staggering loss of over $2.2 billion in market capitalization.

The Invitation for Investors

Hagens Berman is actively encouraging all investors who purchased shares in GRAIL during the defined class period, which spanned from May 13, 2025, to February 19, 2026, to evaluate their losses and consider taking action. There’s a pressing deadline approaching on August 4, 2026, for potential lead plaintiffs wishing to participate in the ongoing litigation effort. Investors are invited to submit their losses and share any relevant information about GRAIL's NHS-Galleri trial to the investigation team.

Reed Kathrein, the partner leading the investigation, emphasized the necessity of determining when GRAIL and its management became aware of the trial's limitations diverging from their public assertions about its efficacy.

Whistleblower Program

Additionally, individuals who possess non-public insights regarding GRAIL's operations are encouraged to reach out and potentially assist in the investigation. The SEC's Whistleblower program offers significant rewards for those who provide original information leading to successful enforcement actions, including payouts of up to 30% from any recoveries obtained by the SEC.

About Hagens Berman

Hagens Berman is a globally recognized firm specializing in complex litigation aimed at upholding corporate accountability. With a strong focus on protecting investors, workers, consumers, and whistleblowers, the firm has successfully secured more than $2.9 billion in recoveries on behalf of its clients. For more details on the ongoing GRAIL investigation and to stay updated on developments, follow @ClassActionLaw on social platforms or visit hbsslaw.com.

In conclusion, affected investors at GRAIL have a critical opportunity to stand up against alleged corporate misconduct and restore their rights through this class action lawsuit led by Hagens Berman. The time to act is now; don’t miss out on your chance for restitution.